The development of Taransgene's AIDS therapeutic vaccine has been advancing rapidly with technology optimization nearing completion. The vaccine has crossed its first significant milestone in demonstrating its efficiency and effectiveness in selective killing of more than 75 per cent of the targeted HIV infected B cells within 48 hours of administration.

With technology optimization nearing completion and supported by the exciting and existing cytotoxicity data, Transgene is readying to take this HIV vaccine forward to pre-clinical studies shortly.

Over the past 27 years, nearly 25 million people have died from AIDS. In 2008, globally, about 2 million people died of AIDS, 33.4 million million were living with HIV and 2.7 million people were newly infected with the virus.

The management hopes that this vaccine, devoid of none or minimal side effects, unlike the current anti-retroviral drugs, in effect revolutionizes the treatment of HIV infected people in so far as not only to arrest the progression of AIDS, but more significantly in reversing the process of AIDS disease itself.

This vaccine, based on Transgene's proprietary auto-immune technology platform is employed in the development of another novel drug – drug for multiple sclerosis.

Transgene has been making steady and significant progress on other novel drugs too such as liver, breast and colon cancers etc, based on its proprietary technology platforms, as also its development of oral insulin.